TQJ230 + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Conditions
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Trial Timeline
Apr 24, 2024 → Mar 31, 2026
NCT ID
NCT06267560About TQJ230 + Placebo
TQJ230 + Placebo is a phase 3 stage product being developed by Novartis for Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease. The current trial status is active. This product is registered under clinical trial identifier NCT06267560. Target conditions include Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06267560 | Phase 3 | Active |
| NCT04023552 | Phase 3 | Active |
Competing Products
12 competing products in Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Muvalaplin + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib | Eli Lilly | Pre-clinical | 23 |
| Rosuvastatin | AstraZeneca | Phase 3 | 77 |
| LIK066 + Placebo | Novartis | Phase 2 | 52 |
| Olpasiran | Amgen | Phase 1 | 32 |
| Maridebart cafraglutide + Placebo | Amgen | Phase 2 | 51 |
| Ivabradine | Amgen | Phase 3 | 76 |
| ALN-PCS02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| ISIS-APO(a)Rx + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| APOC-III-L-Rx + Placebo Comparator | Ionis Pharmaceuticals | Phase 1 | 30 |
| ISIS 681257 + Placebo | Ionis Pharmaceuticals | Phase 2 | 49 |
| IONIS-APO(a)-LRx + Sterile Normal Saline (0.9% NaCl) | Ionis Pharmaceuticals | Phase 1 | 30 |